GT Biopharma, Inc.
GTBP
$0.42
-$0.01-1.69%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -160.55% | -115.42% | 26.33% | 17.25% | -21.13% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 11,983.45% | 2,970.18% | -402.69% | -12,955.56% | 86.03% |
| Change in Net Operating Assets | -17.86% | -211.11% | -2,653.85% | 142.94% | 66.28% |
| Cash from Operations | -20.44% | -0.08% | 8.99% | 11.01% | -8.25% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -99.99% | -100.00% | -21.52% |
| Cash from Investing | -- | -- | -99.99% | -100.00% | -21.52% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 51.92% | 84.68% | -64.65% | -64.65% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 449.53% | 430.07% | 151.01% | 118.18% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,191.14% | -3.51% | -200.70% | -160.60% | 634.74% |